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esponsibility of InstAbstract Ulcerative colitis and Crohn's disease are collectively known as inﬂammatory bowel diseases
(IBD) which are chronic inﬂammatory disorders of gastrointestinal tract. The etiopathogenesis of IBD has
been extensively studied but not fully revealed. Recent advances in physiology, molecular biology and
pharmacology have provided some insight into the basic etiopathogenetic causes such as genetic,
immunologic, etc. This review focuses on drugs involved in the cause of the disease and the
investigational new drugs, current therapeutic strategies and their clinical beneﬁts.
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Inﬂammatory bowel disease (IBD) is usually characterized as
Crohn's disease (CD) and Ulcerative colitis (UC) which involves
spontaneous and uncontrolled inﬂammation of intestinal mucosa
once it is activated. UC was ﬁrstly described by the London
physician, Sir Samuel Wilks in 1859, in which the inﬂammation
was restricted to the colon. CD was ﬁrst observed by the German
surgeon Wilhelm Fabry in 1623, and later described and named
after the New York physician Dr. Burril B. Crohn, in which any
part of gastrointestinal tract (GIT) can be affected. Recently, global
prevalence of IBD has been reached to 36.9 per million persons1.
The highest annual incidence as well as prevalence is also reported
in Europe (incidence: 2.43 per million persons for UC; 1.27 per
million persons for CD, prevalence: 50.5 per million persons for
UC; 32.2 per million persons for CD)2. Apart from the western
countries, its incidence has also been rising in the Asian
countries3. A study in Punjab (North India) also showed
prevalence and incidence rates of 4.43 per million and 0.6 per
million respectively4. The clinical distinctions between UC and
CD have been discussed elsewhere5 and precise etiopathogenesis
still remains elusive6. The factors which are responsible for the
occurrence or progression of IBD include environmental, genetic,
familial and immunity related. Apart from these eosinophils7,
ﬁbroblasts8 and some drugs also play an important role in the
development of IBD. The present review focuses on the drugs
which are involved in the development of IBD, current therapeutic
options along with those which are at the various stages of clinical
trials.2. Drug induced inﬂammatory bowel like diseases
Drugs that have been linked to cause or worsen IBD like
conditions include isotretinoin, antibiotics, non-steroidal anti-
inﬂammatory drugs (NSAIDs), oral contraceptives, mycophenolate
mofetil, etanercept, ipilimumab, rituximab and sodium phosphate.
The pathophysiological mechanisms by which these drugs induce
the disease have been discussed.
2.1. Isotretinoin
It is a synthetic analog of vitamin-A indicated for the treatment of
severe recalcitrant nodular acne9. In vitro studies showed an
inhibitory effect on the release of inﬂammatory mediators and to
prevent the accumulation of neutrophils in acneiform lesions10,11.
In GIT, this inhibitory effect might impair the innate immune
response to the luminal bacterial stimulation and lead to an
exaggerated immune response12. In a recent study, a 27-year-old
female showed chronic inﬂammation of colon with cryptitis after
the treatment with isotretinoin13.
2.2. Antibiotics
Usually, GIT contains about 1013–1014 bacteria that play an
important role in the development of immune system by encoura-
ging immune tolerance14. A recent study showed that these
antibiotics alter the gut microbiota and may contribute to IBD15.
In IBD patients, there is a different mix and number of organisms
with decreased complexity of commensal bacteria16. A dose-
dependent relationship between the number of antibiotic dispensa-
tions and the risk of IBD was reported. Of all antibiotics, penicillinis having a weakest association and metronidazole is having the
strongest17.2.3. NSAIDs
The most common extraintestinal manifestation includes arthro-
pathy. Thirty percent of IBD patients suffer from arthritis, who are
preferably treated by NSAIDs18. So, there is a chance of
exacerbation or even precipitation of new cases19,20. They act by
inhibiting cyclooxygenase (COX) and thus the prostaglandins that
play an important role in mucosal defense mechanisms. Apart
from the above, entero-hepatic circulation of NSAIDs leads to
damage of membrane phospholipids, uncoupling of enterocyte
coupling of mitochondrial oxidative phosphorylation to reduction
in ATP levels, loss of membrane integrity and increased intestinal
permeability21. A case study reported that regular aspirin results in
CD, but not UC22.2.4. Oral contraceptives (OCs)
They usually contain estrogen, progesterone in combination or
alone. The pro-inﬂammatory effects of estrogen like promotion of
B cells, neoangiogenesis, and anti-apoptotic effects on immune
cells increase the risk of developing IBD23. Majority of studies
showed a greater association of OCs with CD than UC24.2.5. Mycophenolate mofetil (MMF)
It is an immunosuppressive agent indicated for the prophylaxis of
organ rejection in renal, cardiac and liver transplantation25. It is
also used in the treatment of auto-immune diseases such as
myasthenia gravis and systemic lupus erythematoses26,27. It is a
pro-drug of mycophenolic acid (MPA) which inhibits de novo
purine synthesis by blocking an enzyme inosine-5′-phosphate
dehydrogenase (INPHD)27. The main side effects include gastro-
intestinal disorders which might be caused by MPA and metabolite
acyl mycophenolic acid glucuronide (AcMPAG)28. The latter
causes toxicity by an irreversible binding to plasma proteins,
lipids and nucleic acids29. In vitro studies showed an increase in
the levels of interleukin-6 (IL-6) and tumor necrosis factor-alpha
(TNFα)28. Studies reported MMF-induced diarrhea in 20 renal
transplanted patients30. Colonic mucosal biopsies showed histolo-
gical alterations in MMF-patients which are characteristic of CD31.
So, once the etiology is ﬁgured out then the discontinuation of
MMF can be done which is usually associated with improvement
in most of the patients.2.6. Ipilimumab
It is a human IgG1 antibody against cytotoxic T-lymphocyte
antigen 4 (CTLA-4) and usually indicated in the treatment of
melanoma. CTLA-4 plays a key role in regulating the adaptive
immune responses by competing with cluster of differentiation
(CD28) on T cells and down-regulates T-cell activation by binding
to B732. In a cohort study done in 198 patients who received
ipilimumab as a treatment showed three patterns of inﬂammation:
neutrophilic (46%), lymphocytic (15%) and both (38%)33. Another
study reported diarrhea or colitis in the ﬁrst 16 weeks of
ipilimumab treatment34.
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It is a chimeric anti-CD20 monoclonal antibody indicated for the
treatment of B-cell non-Hodgkins lymphoma and rheumatoid
arthritis. Its efﬁcacy has been evaluated in steroid refractory UC
patients, which showed well tolerance and no signiﬁcant reduction
in remission35. In contrast, another study reported aggravated UC
after the treatment36. A 4-year-old boy developed severe ulcerative
gastrointestinal disease with deep ulcers after 42 days of
treatment37. A lupus patient also developed diarrhea after 3rd
infusion38. It does not seem to have a beneﬁciary effect in IBD due
to some case reports showing triggering UC-like colitis.
2.8. Etanercept
It is a TNF-receptor fusion protein, found to be ineffective in
treatment of CD but not in rheumatoid disorders. Its use in
ankylosing spondylitis patients showed an increase in the genetic
predisposition to IBD due to enhanced levels of interferon gamma
(INFγ) positive, TNFα positive, mature T-helper cells with cluster
of differentiation 4 cells (CD4+ T cells) and mature T-helper cells
with cluster of differentiation 8 cells (CD8+ T cells)39. Another
case reported the development of new onset of IBD in a mean time
of 29.3 months after the start of the therapy40. Based on these
reports, the incidence of etanercept induced IBD is 43 times
greater than that in the general patient population41.
2.9. Sodium phosphate
It is a hyper-osmotic solution used as a part of colorectal cleansing
preparation42. A study has been conducted, which showed non-
speciﬁc aphthoid lesions similar to CD when given to patients for
colonoscopy43. This is due to toxic effect on mucosa44. The
lesions have a characteristic pigmented halo marking with the
background normal mucosa. They also include apoptotic bodies
instead of chronic inﬂammatory cells45.3. Therapeutic considerations
Of various factors contributing to IBD, drug therapy is limited
only to immune and microbiota mediated which includes anti-
biotics and probiotics against the latter whereas biologics and
antibodies against the former. From the pure market value
perspective, the IBD market value in the seven major markets
(US, Japan, UK, Germany, France, Italy, and Spain) have reached
3.5 billion USD in 2009 which might further grow to 5.6 billion
USD by 2019. So, a lot of companies have been generating new
chemical entities by modifying the release proﬁle of a known drug
or by neutralizing the cytokines, receptors or signaling molecule
which act as secondary messengers in inﬂammatory process.
The standard drug therapy for IBD includes aminosalicylates,
corticosteroids, immunomodulators and biologicals. The drugs
which are already in the market for the treatment of IBD have
been discussed in Table 1. A recent study reported that use of
biologics (especially TNFα inhibitors) in the early stages of CD
leads to less use of corticosteroids and also CD related surgeries in
the later stages of disease46. Apart from the drug therapy, new
emerging therapy includes eggs of Trichris suis when administered
to IBD patients resulted in down-regulation of intestinal inﬂam-
mation47 and laproscopic restorative colectomy which showed asigniﬁcant return to normal bowel function, shorter hospitalization
periods when compared with the open proctocolectomy groups48.
3.1. Aminosalicylates
These are ﬁrst-line of therapy indicated for the maintenance of
remission in UC49, acting on epithelial cells by a variety of
mechanisms to restrain the release of lipid mediators, cytokines
and reactive oxygen species. The drugs involve mesalamine
(5-aminosalicyclic acid, 5-ASA). The most primitive member of
this class includes sulfasalzine which consists of 5-ASA linked to
sulfapyridine by an azo bond. When it reaches the colon, the azo
bond is cleaved by bacterial azoreductases releasing the active
moiety, 5-ASA and an inactive moiety, sulfapyridine. Sulfapyr-
idine is absorbed and metabolized by hepatic acetylation or
hydroxylation followed by glucuronidation. Even though inactive,
it had side effects. So, in order to prevent the side effects of
sulfapyridine and also to improve the therapeutic efﬁcacy,
olsalazine (Dipentium) has been developed which has two
molecules of mesalamine bound by an azo bond. Later, balsalazide
(Coalazal, Giazo) was developed in which the inert carrier
4-aminobenzoyl-β-alanine has been bonded to the active moiety.
Usual dose of mesalamine is 4 g/day, dividing to four separate
doses taken with food in order to reduce the adverse effects.
The dose can be increased to a maximum of 6 g/day but as the
dose rises, side effects also increase. Olsalazine is usually
administered at 1 g/day in 2 divided doses and balsalazide at
6 g/day50. In order to control the release of mesalamine in the
colon and to reduce the side effects, various formulations have
been developed which include: (1) pH dependent release/resin
coated (Asacol, Asacol HD, Apriso, Lialda, Delzicol) and (2) time
controlled release (Pentasa).
The role of 5-ASA preparations in remission of CD is
controversial. As some studies reported their role in induction of
remission of CD and that higher doses than those typically used in
UC are used51. Apart from tablets and capsules, mesalamine is also
presented as enemas (Cortenema) and suppositories (Cortifoam)
which are superior to hydrocortisone enemas. Dose of enema is
usually 4 g/60 mL and should be used at bed time with a retention
time of at least 8 h. Suppository should be used 2–3 times with a
retention time of 3 h and a dose of around 500 mg. These
formulations show response within 3–21 days. It continued until
6 weeks for remission and afterwards lower doses can be used for
maintenance.
Side effects of sulfasalazine occur due to dose in 10–45% of
UC patients which includes headache, nausea and fatigue. Serious
idiosyncratic allergic reactions like rash, fever, Stevens Johnson
syndrome, pancretitis, agranulocytosis or alveolitis are rare to
happen. It also inhibits intestinal folate absorption; and so folate is
usually given as a supplement52. Diarrhea is the common side
effect for olsalazine, which is its ability to stimulate chloride and
ﬂuid secretion in small intestine. Even though sulfasalazine and its
metabolites have the ability to cross the placenta but they have not
shown fetal risk. The newer formulations are well tolerated and the
side effects are relatively infrequent in which headache, dyspepsia
and skin rash are the most common ones.
3.2. Corticosteroids
These are the drugs indicated for the treatment of mild to moderate
active UC and CD53. These include prednisone, budesonide (given
Table 1 Drugs available in the market for the treatment of IBD.
Drug class Drug name Company name Strength Dosage form Dose Indication Mechanism of action
Aminosalicylates Mesalamine Apriso Salix Pharms 375 mg Capsule, ER, oral 1.5 g/day Maintenance remission of
UC in adults
5-ASA blocks the production of AA
metabolites.Asacol Warner Chilcott
LLC
400 mg Tablet, DR, oral 2.4 g/day for about
6 weeks
Asacol HD Warner Chilcott
LLC
800 mg Tablet, DR, oral 4.8 g/day for about
6 weeks
In vitro: inhibits IL-1, TNFα
production along with LOX pathway inhibition
and NF-κB inhibition.Canasa Aptalis Pharma US 500 mg Suppository, rectal 1–1.5 g/day
Lialda Shire 1.2 g Tablet, DR, oral 2–4 tablets (1.2 g)/
day
Rowasa Meda Pharms 4 g/60 mL Enema, rectal NA
Pentasa Shire 250,
500 mg
Capsule, ER, oral 1 g/4 times a day
Delzicol Warner Chilcott 400 mg Capsule, DR, oral 2.4 g/day, 800 mg
3 times a day
Olsalazine Dipentum Meda pharms 250 mg Capsule, oral 1 g/day in 2 divided
doses
Maintenance of remission
of UC in patients who are
intolerant of sulfasalazine
Olsalazine is converted to sulfapyridine and
mesalamine (active moiety) by azo reductases.
Balsalazide Colazal Salix Pharms 750 mg Capsule, oral 6.75 g/day
for 8 weeks
Treatment of mildly to
moderately active UC
Balsalazide is converted to mesalamine (active
moiety) and 4-aminobenzoyl-β-alanine (carrier
moiety) by bacterial azoreductases.Giazo Salix Pharms 1.1 g Tablets, oral 6.6 g/day
for 8 weeks
Corticosteroids Budesonide Entocort EC AstraZeneca 3 mg Capsule, oral 9 mg once daily in
the morning for up to
8 weeks
Mild to moderate active
CD
Glucocorticoid activity.
Uceris Santarus 9 mg Tablet, oral 9 mg once daily in
the morning for up to
8 weeks
Treatment of mildly to
moderately active UC
Prednisone Rayos Horizon Pharma 1 mg,
2 mg,
5 mg
Tablet, DR, oral 5 mg once daily Immunosuppresive agent
for acute episodes of UC
and CD
Corticosteroid activity with inhibition in
inﬂammatory processes.
Biologicals Inﬂiximab Remicade Centcor Inc. 100 mg Injection, iv. use 5 mg/kg at 0, 2 and 6
week, then every 8
weeks
UC, CD with moderately
and severly active
It binds to TNFα and neutralizes its activity.
Adalimumab Humira Abbott 40 mg/
0.8 mL
Injection, sc. use Day 1: 160 mg; Day
15: 80 mg; Day 29:
40 mg every other
week (Maintenance
dose)
CD, UC who are non-
responsive to conventional
therapy
Binds to TNFα and blocks its interaction with the
p55 and p75 cell surface TNF receptors. It does
not bind to TNFβ receptors.
Golimumab Simponi Centocor Ortho
Biotech Inc.
50 mg/
0.5 mL
Injection, sc. use UC Binds to both the soluble and transmembrane
bioactive forms of human TNFα. This interaction
prevents the binding of TNFα to its receptors,
thereby inhibiting the biological activity of TNFα
(a cytokine protein).
Abbreviations: ER, extended release; DR, delayed release.
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Drugs as causative agents and therapeutic agents in IBD 293orally). In order to reduce the systemic side effects and to enhance
the local colonic effect, various formulations have been developed.
Depending on the responsiveness of the patients to the steroids,
they are categorized to steroid-responsive (40%) where the patients
show clinical improvement and remission once the dose is tapered;
steroid-dependent (20%) where tapering of dose leads to revival
of symptoms after initial response to glucocorticoids; steroid-
independent where the patient does not respond to steroid therapy
due to up-regulated levels of mdr gene or altered levels of
corticosteroid binding globulin54. They act by inhibiting several
inﬂammatory pathways-interleukin suppression, arachidonic acid
metabolism suppression and stimulation of apoptosis of lympho-
cytes within the lamina propria of the gut.
The initial dose for prednisone is 40–60 mg/day and gradually
tapered within weeks to months. The adverse effects have been
observed with a dose higher than 40 mg/day which include
moonface, acne, edema and sleep and mood disturbances in early
stages. In long term therapy, visual changes are observed because
of steroid-induced hyperglycemia (cataract), osteoporosis, osteo-
necrosis and increased susceptibility to infection.
An enteric form of budesonide (Entocort, EC) has been
developed for ileocecal CD. It is formulated to release the
minimum amount of drug in the inﬂamed portions of intestine to
exert a local effect and minimize the systemic effects caused by
extensive ﬁrst pass metabolism (10% systemic bioavailability)55.
Similarly, by using multi matrix release technology (MMX) and
enteric coating, another formulation of budesonide has been
developed (Uceris) and launched recently which showed greater
colonic delivery of the active substance56.
In patients with ulcerative proctosigmoiditis where the inﬂam-
mation is limited to left colon and rectum, glucocorticoid enemas
are useful, although more expensive and slightly less effective than
5-ASA enemas. Dose of hydrocortisone enema is 100 mg/60 mL
and the usual dose is 60 mL enema/night for every 2–3 weeks.
Response is usually seen in 3–7 days. This can also be given as a
foam suspension which delivers 80 mg of drug per application and
particularly useful in patients who are having difﬁculty in retaining
ﬂuids.
3.3. Immunosuppressants
The drugs which have been developed as anticancer agents
initially are utilized in the treatment of IBD. They are used in
patients who are unresponsive to steroids and aminosalicylates or
in those in which the disease relapses when steroids are with-
drawn. Even though they have signiﬁcant side effects, they are
safer and better tolerated than long-term corticosteroid therapy.
Prior to the start of the therapy, their use, side effects and other
alternatives have to be discussed with the patient especially the
aspect of risk to beneﬁt ratio.
3.3.1. Azathioprine (AZA) and 6-mercaptopurine (6-MP)
These are cytotoxic drugs useful in the treatment of CD but their
role in UC is less available57,58. Azathioprine is converted to
6-mercaptopurine by the liver metabolizing enzymes, which are
further metabolized to 6-thioguanine nucleotides. These metabo-
lites inhibit the purine biosynthesis and in turn T-cell proliferation.
Usually, the oral tolerated dose of azathioprine is 2–2.5 mg/kg and
mercaptopurine is 1.5 mg/kg. The initial dosage for both drugs is
50 mg. Therapeutic efﬁcacy is shown at a dose of 50–100 mg/day
for mercaptopurine and 75–100 mg/day for azathioprine. The mostcommon side effects include headache, myalgia, nausea and
diarrhea. In some patients (3–5%), drug induced pancreatitis has
been reported59. Rarely, leukemia has also been developed
suddenly in some patients and a signiﬁcant association has been
failed to link the development of leukemia and the usage of
azathioprine60.
3.3.2. Methotrexate
This is used as a disease modifying anti-rheumatoid drug
(DMARD) in the treatment of rheumatoid arthritis. It is effective
in inducing remission or preventing the relapse of CD particularly
in those who are refractory or intolerant to AZA or 6-MP. It shows
its anti-inﬂammatory activity by inhibiting dehydrofolate reductase
which in turn blocks DNA synthesis and eventually leads to cell
death. It is usually given as an intramuscular injection of
15–25 mg every week. Side effects include nausea, vomiting,
diarrhea, stomatitis, leukopenia and pneumonitis which usually
occur with overdose61.
3.3.3. Cyclosporine
It is a calcineurin inhibitor which inhibits the release of IL-2 and
prevents the formation of cytotoxic lymphocytes. It is used in the
treatment of UC who are refractory to corticosteroid therapy. In
such cases, iv. dose of 2 mg/kg/day converts an emergency
operation situation to a less urgent one. Once the patients have
started to respond to the iv. therapy, they can be maintained on
oral therapy of 5 mg/kg/day. The main limitation of oral cyclos-
porine is limited in intestinal absorption which is enhanced by soft
gelatin capsule (Neoral) developed by Novartis. Therapeutic range
of cyclosporine in blood is 100–200 ng/mL and a careful
monitoring is required. Side effects include tremors, headache,
gum hyperplasia and hirustism62.
3.3.4. Tacrolimus
It is similar to cyclosporine and has enhanced bioavailability than
oral cyclosporine. This can be used in patients with severe CD63.
3.4. Biologicals
The biologicals which are already approved, present in the market
and also at the various stages of clinical trials (mostly) are intended
for the treatment of CD. The ﬁrst product in this class is inﬂiximab
(Remicade) which is a chimeric IgG1κ monoclonal antibody and
speciﬁc for human TNFα. It is indicated for the treatment of
moderately or severely active CD or ﬁstulating CD. Dose is 5 mg/
kg given intravenously at 0, 2nd, 6th week of the induction stage
and 5 mg/kg every 8 weeks thereafter. The same dose is followed
for patients with UC. Side effects include rash, utricaria, ﬂushing
and headache. It has been studied that inﬂiximab develops
antibodies in around 10% of patients, but lupus like syndrome
rarely occurs. It is contraindicated in patients with congestive heart
failure64. The other in line product is adalimumab (Humira) which
is also a fully humanized anti-TNFα antibody and intended for the
treatment of CD given subcutaneously. Dose is 160 mg on day 1,
followed by 80 mg 2 weeks later, then 2 weeks later a maintenance
dose of 40 mg is given every alternate week65. Certolizumab pegol
(Cimzia), humanized Fab antibody fragment linked to polyethy-
lene glycol (PEG) for subcutaneous administration has been
developed. PEGylation increases the half-life of the drug by
14 days. Recent clinical trials showed a modest improvement in
response rates in CD patients when compared with placebo.
P.K. Kondamudi et al.294Another study showed that 400 mg subcutaneous injections 4
times weekly are well tolerated in moderate to severe CD
patients66,67. Natalizumab (Tysabri) is a humanized IgG4κ mono-
clonal antibody produced in murine myeloma cells indicated for
the maintenance and remission in moderate to active CD patients.
It acts by blocking α4 integrin of α4β1 and α4β7 integrins
expressed on the surface of leukocytes and inhibits adhesion of
leukocytes to their counter receptor. The half-life of this molecule
is around 11 days. The major side effects include progressive
multifocal leukoencephalopathy (PML), hypersensitivity, immu-
nosuppression/infections and intestinal obstruction68,69.
The other biological products which are in the various stages of
clinical development include those mentioned as follows.
3.4.1. Drugs in the treatment of UC
3.4.1.1. Tofacitinib. It is a monoclonal antibody and orally active
Janus kinase (JAK) 1, 2 and 3 inhibitor developed by Pﬁzer.
A phase II study, in which the patients have been given 0.5, 3, 5
and 15 mg twice daily showed a dose related clinical and
endoscopic remission at the end of 8 weeks with a dose dependent
rise in low density and high density lipoproteins (LDL and HDL)
which subside once the treatment is discontinued. However, a
large size of population and prolonged study can project a deeper
insight into this issue70.
3.4.1.2. MDX-1100. It is an anti-CXCL (Chemokine ligand)
monoclonal antibody, indicated for treatment in UC. A recent
phase II clinical study, in which the drug has been given
intravenously at a dose of 10 mg/kg every alternative day, showed
that the drugs lack clinical response at day 57 but has a
comparable clinical remission and mucosal healing rates with
placebo71.
3.4.1.3. Tralokinumab. It is an anti-IL-13 monoclonal antibody
developed by MedImmune. It is currently under phase-II clinical
trial where the study is going on.
3.4.2. Drugs in the treatment of CD
3.4.2.1. Fontolizumab. It is a humanized monoclonal anti-body
developed by PDL Biopharma and acts by inhibiting IFNγ.
A phase II study did not show a strong clinical response but
signiﬁcantly showed a biological effect by decreasing a C-reactive
protein and was well tolerated which required further studies to
assess its efﬁcacy72,73.
3.4.2.2. MEDI-2070. It is another monoclonal antibody with
anti-IL-23 antibody activity. It is currently in recruiting volunteers
for phase IIa study in order to evaluate the safety and efﬁcacy of
the moiety.
3.4.2.3. QAX 576. It is an anti-IL-13 antibody developed by
Novartis and currently completed a phase II clinical study.
3.4.2.4. Secukinumab. It is a humanized anti-IL-17A antibody
developed by Novartis Pharma but phase II study showed that it is
ineffective and higher rates of adverse events are observed when
compared with placebo74,75.
3.4.2.5. Ustekinumab. It is an anti-TNFα antibody developed by
Janseen Cilag. A recent study to test the efﬁcacy in CD patients
who are refractory to other TNF antagonists showed an increased
rate of response to induction when compared with placebo76.4. Conclusions
In summary, apart from the known factors like immunity, familial,
genetic and environmental factors, there are other factors includingeosinophils, ﬁbroblasts and some drugs, which give us a deeper
insight into the evasive pathogenesis of the disease. Various
formulations of budesonide and mesalamine are developed (like
Uceriss, Lialdas) in order to have a more local action and reduce the
systemic side-effects. The drug molecules which are in the develop-
ment process (mostly biological) are also targeted against particular
stage or cell which has a key role in the development of the disease.References
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